This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Tony W. Cheung, MD; Henry S. Sacks, PhD, MD
Mount Sinai Medical Center New York, NY

JAMA. 1990;263(8):1067.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Arno et al¹ demonstrated the high cost of early intervention and treatment in human immunodeficiency virus disease. However, their cost estimate did not take into account recent results of AIDS [acquired immunodeficiency syndrome] Clinical Trial Group protocols or the recent reduction in the price of zidovudine. These studies demonstrated that zidovudine slowed the progression of human immunodeficiency virus infection in asymptomatic infection and early AIDS-related complex (ARC) and that lower doses appeared as effective as standard doses. Using these data, we suggest a different cost estimate in taking care of these patients.

Based on a prospective study of 288 seropositive men in San Francisco, Calif,² and the survey of the Greater New York Hospital Association,³ the ratio of ARC to AIDS is approximately 1:1. As of July 1989, the number of patients living with AIDS in the United States is 41000 (lower-bound estimate).⁴ . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?